LGALS3 and metabolic dysfunction-associated steatohepatitis: Regarding the other Gal-inhibitors under clinical investigation, the selective Gal-3 inhibitors GR-MD-02 (8 mg/kg) (NCT03809052, NCT04607655) or GB1211 (10 and 100 mg/kg) were administered orally, twice daily for 12 weeks, to patients with non-alcoholic steatohepatitis (NASH) (NCT02421094).